Long-term Blood Pressure Variability throughout Young Adulthood and Cognitive Function in Midlife; CARDIA study

Similar documents
ORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults

YOUNG ADULT MEN AND MIDDLEaged

Insulin resistance influences 24h heart rate and blood pressure variabilities and cardiovascular autonomic modulation in normotensive healthy adults

University of Padova, Padua, Italy, and HARVEST Study Group, Italy

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand

Depok-Indonesia STEPS Survey 2003

Population models of health impact of combination polypharmacy

Epidemiologic Measure of Association

Excess Body Mass Index- and Waist Circumference-Years and Incident Cardiovascular Disease: The CARDIA Study

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway

Risk Factors for Heart Disease

Metabolic syndrome is a constellation of cardiovascular

Yuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China

Analyzing diastolic and systolic blood pressure individually or jointly?

Seasonal variation in blood pressure and its relationship with outdoor air temperature in 10 diverse regions of China: the China Kadoorie Biobank

RISE, FALL AND RESURRECTION OF RENAL DENERVATION. Michael A. Weber, MD State University of New York Downstate College of Medicine

High intensity exercise improves cardiac structure and function and reduces liver fat in adults with Type 2 diabetes

The Effects of Moderate Intensity Exercise on Lipoprotein-Lipid Profiles of Haramaya University Community

Impact of Lifestyle Modification to Reduce Cardiovascular Disease Event Risk of High Risk Patients with Low Levels of HDL C

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Patient is healthy with no chronic disease or significant risk factors [16%].

Cardiovascular Risk Assessment and Management Making a Difference

Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?

well-targeted primary prevention of cardiovascular disease: an underused high-value intervention?

Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures

Prevalence of Comorbidities among HIV-positive patients in Taiwan

Slide notes: References:

Risk Assessment of developing type 2 diabetes mellitus in patient on antihypertensive medication

Supplementary Material. Serum Chloride is an Independent Predictor of Mortality in Hypertensive Patients

Association between arterial stiffness and cardiovascular risk factors in a pediatric population

Metabolic Syndrome: Bad for the Heart and Bad for the Brain? Kristine Yaffe, MD Univ. of California, San Francisco

Randomized Design of ALLHAT BP Trial

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 64, NO. 10, 2014 ª 2014 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN /$36.

Diabetes Mellitus: A Cardiovascular Disease

Supplementary Online Content

ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study

programme. The DE-PLAN follow up.

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.

Metabolic Syndrome and Workplace Outcome

Joint Impact of Smoking and Hypertension on Cardiovascular Disease and All-Cause Mortality in Japan: NIPPON DATA80, a 19-Year Follow-Up

Alcohol consumption and blood pressure change: 5-year follow-up study of the association in normotensive workers

T. Suithichaiyakul Cardiomed Chula

Diet-Related Factors, Educational Levels and Blood Pressure in a Chinese Population Sample: Findings from the Japan-China Cooperative Research Project

Magnetic resonance imaging, image analysis:visual scoring of white matter

A n aly tical m e t h o d s

Diabetes, Diet and SMI: How can we make a difference?

Blood pressure and total cholesterol level are critical risks especially for hemorrhagic stroke in Akita, Japan.

Atherosclerosis 226 (2013) 214e219. Contents lists available at SciVerse ScienceDirect. Atherosclerosis

Identification of subjects at high risk for cardiovascular disease

The American Heart Association (AHA) 2020 Strategic

Blood Pressure Targets in Diabetes

PREVER STUDY. What we learned with the PREVER-PREVENTION Trial? Dr. Sandra C. Fuchs. Professor at Universidade Federal of Rio Grande do Sul, Brazil

GATEWAY Trial. Bariatric Surgery versus Conventional Medical Treatment in Obese Patients with Hypertension

Dysglycaemia and Hypertension. Dr E M Manuthu Physician Kitale

Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS

Nomogram of the Relation of Brachial-Ankle Pulse Wave Velocity with Blood Pressure

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

Pongamorn Bunnag, MD Boonsong Ongphiphadhanakul, MD. Mahidol University

BLOOD PRESSURE VARIABILITY AND STROKE ADAM DE HAVENON, MD UNIVERSITY OF UTAH

Why Do We Treat Obesity? Epidemiology

SYNOPSIS. Publications No publications at the time of writing this report.

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up

Effects of Bariatric Surgery in Obese Patients with Hypertension The GATEWAY Randomized Trial

Donald M. Lloyd-Jones, MD, ScM a,b, *, Alan R. Dyer, PhD a, Renwei Wang, MS a, Martha L. Daviglus, MD, PhD a, and Philip Greenland, MD a,b

Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital

Case study: Lean adult with no complications, newly diagnosed with type 2 diabetes

Placebo-Controlled Statin Trials Prevention Of CVD in Women"

Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents

Current status on other health effects:

Relations of body weight status in early adulthood and weight changes until middle age with metabolic syndrome in the Chinese population

Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in hs-crp

Effects of Bariatric Surgery in Obese Patients with Hypertension The GATEWAY Randomized Trial

Longitudinal Trajectories of Cholesterol from Midlife through Late Life according to Apolipoprotein E Allele Status

The Evolution To Treatment Of Hypertension With Advanced Formulation

Biomed Environ Sci, 2014; 27(8):

To reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees.

Adolescent Hypertension Roles of obesity and hyperuricemia. Daniel Landau, MD Pediatrics, Soroka University Medical Center

Kidney Stones and Subclinical Atherosclerosis in Young Adults: The CARDIA Study

Prof. Renata Cífková, MD, CSc.

CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES

Supplemental Table S2: Subgroup analysis for IL-6 with BMI in 3 groups

Physical Activity, Sedentary Behaviors and the Incidence of Type 2 Diabetes Mellitus: The Multi-

What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?

Society for Behavioral Medicine 33 rd Annual Meeting New Orleans, LA

The relation between arterial blood pressure (BP) and

Global Coronary Heart Disease Risk Assessment of U.S. Persons With the Metabolic. Syndrome. and Nathan D. Wong, PhD, MPH

Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s

Andrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University

Health Literacy, Cognition & Asthma Self-Management. Rachel O Conor, MPH October 29, 2013

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University

ALLHAT. ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status

INCREASED PULSE PRESSURE AND SYSTOLIC x HEART RATE DOUBLE PRODUCT AND CARDIOVASCULAR AUTONOMIC NEUROPATHY IN TYPE 2 DIABETIC PATIENTS

Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography

Cardiovascular Diseases in CKD

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH

Causes of Poor BP control Rates

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

Transcription:

The EPI/NPAM Spring 2014 Scientific Sessions, Hilton San Francisco Union Square, San Francisco, CA Northwestern Mar. 18-21, 2014 University Feinberg School of Medicine Long-term Blood Pressure Variability throughout Young Adulthood and Cognitive Function in Midlife; CARDIA study Yuichiro Yano, MD, 1 Hongyan Ning, MD, MS, 1 Norrina Allen, PhD, 1 MPH, Jared P. Reis, PhD, 2 Lenore J. Launer, PhD, 3 Kiang Liu, PhD, 1 Kristine Yaffe, MD, 4 Philip Greenland, MD, 1 and Donald Lloyd-Jones MD, ScM 1 1. Department of Preventive Medicine, Northwestern University Feinberg School of Medicine 2. Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute 3. Laboratory of Epidemiology, Demography, and Biometry, National Institute on Aging 4. Department of Psychiatry, University of California, San Francisco, CA, US

Presenter Disclosure Information Elements Yuichiro Yano, MD Department of Preventive Medicine, Northwestern University Feinberg School of Medicine FINANCIAL DISCLOSURE: Manpei Suzuki International Prize for Diabetes Research

BP variability (BPV) Short-term BPV (e.g., beat-to-beat and within 24-hours) Long-term BPV (e.g., day-by-day, visit-to-visit (monthly, yearly) BPV). Parati G. Nat Rev Cardiol. 2013;10(3):143.

Background The association of long-term (1-8 years) BPV with cognitive dysfunction has been recently reported among elderly and highrisk populations. 1-3 The association of long-term BPV with cognitive function in young adults remains uncertain 1. Sabayan et al., BMJ. 2013;347:f4600. 2. Alpérovitch et al.,alzheimers Dement. 2013. pii: S1552-5260(13)02474-6. 3. Nagai M, et al. J Hypertens. 2012;30(8):1556-1563.

Objectives We sought to determine whether: Long-term BPV throughout young adulthood (25 years) is associated with cognitive function in midlife Diverse domains of cognition (i.e., psychomotor speed, verbal memory, and executive function) are differentially associated with long-term BPV

Longitudinal study of lifestyle and the evolution of CVD risk factors in young adults 5,115 black and white men and women of varying educational attainment Aged 18 30 at baseline (1985 1986) Four study centers: Chicago IL, Birmingham AL, Minneapolis MN, Oakland CA Follow-up examinations at years 2, 5, 7, 10, 15, 20, 25

BPV measurements Average real variability (ARV) ( Δ1 + Δ2 + Δ3 + Δ4 + Δ5 + Δ6 + Δ7 ) / 7 SBP, mmhg 130 120 110 100 Mean SBP across 8 visits SBP M1 Δ1 M2 M3 Δ2 Δ3 Minimum SBP M4 Δ4 M5 Δ5 Maximum SBP M6 Δ6 M7 Cumulative exposure of SBP Δ7 Standard deviation (+coefficient of variation) Y 0 Y 2 Y 5 Y 7 Y 10 Y 15 Y 20 Y 25 Cumulative exposure of BP; (M1 2year+ M2 3year + M3 2year + M4 3year + M5 5year + M6 5year + M7 5year)

Outcomes Cognitive function was assessed (n=2,326) at Y 25 with Digit Symbol Substitution Test (DSST, psychomotor speed test), Rey Auditory Verbal Learning Test (RAVLT, verbal memory test) Modified Stroop test (executive function test)

Baseline characteristics of participants (n=2,326) Age, years 25.3+3.5 Men, % 43.3 Blacks, % 40.2 Education, years 14.3+2.2 Body mass index, kg/m 2 24.4+4.7 Current smoker, % 5.7 Current drinker, % 61.5 Physical activity, exercise units 424.7+296.9 Antihypertensive medication, % 1.9 SBP, mmhg 109.8+10.8 DBP, mmhg 68.5+9.2 Fasting glucose, mg/dl 82.1+11.4 Total cholesterol, mg/dl 177.7+32.8 High-density lipoprotein, mg/dl 53.3+12.6 Data are expressed as the means ± SD or percentage.

Age, sex, and race-adjusted correlation of SD BP and ARV BP with the demographics and clinical characteristics (n=2,326) SD SBP, mmhg SD DBP, mmhg ARV SBP, mmhg Demographics at Y 0 Education, years -.10 *** -.10 *** -.13 *** -.11 *** Clinical characteristics at Y 25 Body mass index, kg/m 2.17 ***.21 ***.12 ***.10 *** Physical activity, -.07 ** -.06 ** -.06 ** -.04 ARV DBP, mmhg exercise units Fasting glucose, mg/dl.11 ***.10 ***.13 ***.06 ** Total cholesterol, mg/dl.04.03 -.01.003 High-density lipoprotein, mg/dl -.09 *** -.10 *** -.07 *** -.05 * Pearson s correlation coefficients adjusted by age, sex, and race are shown. SD and ARV were calculated by BP measures across 8 visits (Y 0-25 ). * P<.05; ** P <.01; *** P<.001.

Mean (95% CIs) scores of cognitive function test by deciles of ARV BP Digit Symbol Substitution Test (symbols) ARV SBP P for trend ARV DBP P=.0004 for trend Lower score means lower Psychomotor speed Rey Auditory Verbal Learning Test (words) P=.04 P=.02 Lower score means lower verbal memory Stroop test (sec + errors) P=.03 P=.41 Higher score means lower executive function Deciles of ARV SBP Deciles of ARV DBP Adjusted for age, sex, race, education, and study site.

Mean (95% CIs) scores of cognitive function test by deciles of SD BP Digit Symbol Substitution Test (symbols) SD SBP P=.01 for trend SD DBP P=.003 for trend Lower score means lower Psychomotor speed Rey Auditory Verbal Learning Test (words) P=.08 P=.003 Lower score means lower verbal memory Stroop test (sec + errors) P=.23 P=.18 Higher score means lower executive function Deciles of SD SBP Deciles of SD DBP Adjusted for age, sex, race, education, and study site

Linear regression models to examine the associations of BPV with cognitive function (n=2,326) Model 1 (Unadjusted) P β (SE) value Digit Symbol Substitution Test (symbols); Model 2 Model 3 Model 4 β (SE) P value β (SE) P value β (SE) P value Lower score means lower Psychomotor speed test SD SBP SD DBP -.047 (.005) -.068 (.007) -.022 (.004) -.034 (.006) -.022 (.006) -.030 (.008) <.001 -.017 (.005) -.029 (.007) ARV SBP -.064 (.006) -.033 (.005) -.026 (.006) -.025 (.006) ARV DBP -.067 (.007) -.034 (.006) -.028 (.007) -.029 (.007) Rey Auditory Verbal Learning Test (words): Lower score means lower verbal memory test <.01 SD SBP SD DBP -.029 (.005) -.056 (.007) -.013 (.005) -.024 (.007) <.01 <0.001 -.010 (.007) -.018 (.008) ARV SBP -.044 (.006) -.021 (.005) -.016 (.006) ARV DBP -.055 (.007) -.026 (.007) <0.001 -.020 (.007) β means standardized regression coefficient. As adjustment factors, Model 2 includes age at baseline, sex, race, education, and study center.13 <.05 <.05 <.01 -.008 (.005) -.019 (.007) -.016 (.006) -.021 (.007).12 <.01 <.05 <.01 Model 3 includes model 2+ clinical characteristics at Y 25 (BMI, smoking, alcohol, physical activity, fasting glucose, total cholesterol/hdl, use of antihypertensive drugs, incidence of stroke) + BP (Y 0 ) and change of BP (Y 25 -Y 0 ) Model 4 included model 2+ clinical characteristics at Y 25 + cumulative exposure of BP (Y 0-25 ).

Linear regression models to examine the associations of BPV with cognitive function (n=2,326) Model 1 (Unadjusted) Model 2 Model 3 Model 4 β (SE) P value β (SE) P value β (SE) P value β (SE) P value Stroop test (sec + errors): Higher score means lower executive function test SD SBP.042 (.005) SD DBP.051 (.007).013 (.005).013 (.007) <.01 0.053.002 (.007).004 (.008).73.61.004 (.005).004 (.007).41.60 ARV SBP.045 (.006) ARV DBP.043 (.007).015 (.006).011 (.007) <.01 0.12.004 (.006).004 (.007).52.54.004 (.006).004 (.007).50.53 β means standardized regression coefficient, and R 2 means a measure for the model prediction. As adjustment factors, Model 2 includes age at baseline, sex, race, education, and study center Model 3 includes model 2+ clinical characteristics at Y 25 (BMI, smoking, alcohol, physical activity, fasting glucose, total cholesterol/hdl, use of antihypertensive drugs, incidence of stroke) + BP (Y 0 ) and change of BP (Y 25 -Y 0 ) Model 4 included model 2+ clinical characteristics at Y 25 + cumulative exposure of BP (Y 0-25 ).

Strengths and Limitations Strengths CARDIA cohort, a well phenotyped longitudinal cohort with high-quality measures of BP and cognitive function Limitations We could not assess change in cognitive function over time A number of people from the original cohort were excluded in the present analysis (55%)

Summary and Conclusions Higher long-term BPV throughout young adulthood (25 years 50 years) is associated with lower function of psychomotor speed (i.e., DSST) and verbal memory (i.e., RAVLT) in midlife. These data suggest the testable hypothesis that reduction of BPV throughout the young adults could lead to improvement in cognitive function in midlife

Thank you

Backup

Correlation of SD BP with CV BP and MMD BP (n=2,326) SD SBP, mmhg SD DBP, mmhg CV SBP, mmhg.98 ***.61 *** CV DBP, mmhg.54 ***.96 *** MMD SBP, mmhg.98 ***.63 *** MMD DBP, mmhg.63 ***.97 *** Pearson s correlation coefficients are shown. SBP indicates systolic blood pressure; DBP, diastolic blood pressure; SD; standard deviation, CV; coefficient of variation, MMD; maximum and minimum BP difference. *** P<0.001.

Age, sex, and race-adjusted correlation of SD BP and ARV BP with the demographics and clinical characteristics (n=2,326) SD SBP, mmhg SD DBP, mmhg ARV SBP, mmhg ARV DBP, mmhg Demographics at Y 0 Education, years -.10 *** -.10 *** -.13 *** -.11 *** Demographics at Y 25 Body mass index, kg/m 2.17 ***.21 ***.12 ***.10 *** Physical activity, exercise units -.07 ** -.06 ** -.06 ** -.04 Fasting glucose, mg/dl.11 ***.10 ***.13 ***.06 ** Total cholesterol, mg/dl.04.03 -.01.003 High-density lipoprotein, mg/dl -.09 *** -.10 *** -.07 *** -.05 * BP parameters Change of SBP (Y 25 -Y 0 ), mmhg.59 ***.36 ***.22 ***.12 *** Change of DBP (Y 25 -Y 0 ), mmhg.42 ***.47 ***.15 ***.17 *** Average SBP (Y 0-25 ), mmhg.48 ***.41 ***.43 ***.30 *** Average DBP (Y 0-25 ), mmhg.40 ***.28 ***.38 ***.19 *** Cumulative exposure of.52 ***.44 ***.44 ***.31 *** SBP (Y 0-25 ), mmhg Cumulative exposure of DBP (Y 0-25 ), mmhg.44 ***.35 ***.38 ***.22 *** Pearson s correlation coefficients adjusted by age, sex, and race are shown. SD and ARV were calculated by BP measures across 8 visits (Y 0-25 ). * P<.05; ** P <.01; *** P<.001.

Mean (95% CIs) scores of cognitive function test with adjustment for age, sex, race, education, and study site in deciles of ARV BP Digit Symbol Substitution Test (symbols) P for trend P=.0004 for trend Lower score means lower Psychomotor speed test Rey Auditory Verbal Learning Test (words) P=.04 P=.02 Lower score means lower verbal memory test Stroop test (sec + errors) P=.03 P=.41 Higher score means lower executive function test Deciles of ARV SBP Deciles of ARV DBP The range of ARV divided by deciles. 1 st 2 nd 3 rd 4 th 5 th 6 th 7 th 8 th 9 th 10 th Mean+SD ARV SBP, 1.2-4.4 4.4-5.3 5.3-6.0 6.0-6.7 6.7-7.4 7.4-8.2 8.2-9.1 9.1-10.3 10.3-12.4 12.4-48.4 8.0+3.5 mmhg (n=232) (n=233) (n=233) (n=228) (n=235) (n=235) (n=228) (n=235) (n=234) (n=233) ARV DBP, mmhg 1.3-4.0 (n=232) 4.0-4.8 (n=233) 4.8-5.5 (n=233) 5.5-6.1 (n=235) 6.1-6.9 (n=219) 6.9-7.4 (n=244) 7.4-8.3 (n=231) 8.3-9.3 (n=233) 9.3-11.0 (n=234) 11.0-22.3 (n=232) 7.2+2.8